Table 1 Patient characteristics CLL no.... | American Society of Hematology

Table 1

Patient characteristics

CLL no.	CD19*	CD5†	ZAP-70‡	CD38§	11q (ATM)	17p (p53)	13q
1	95	87	19	ND	ND	N	ND
2	94	100	42	17	N	N	N
3	94	100	72	16	N	N	del (95%)
4	92	96	30	ND	ND	ND	ND
5	86	60	100	85	N	N	N
6	96	98	64	74	del (90%)	N	N
7	91	69	29	7	N	N	N
8	94	99	41	26	ND	N	ND
9	99	100	32	14	ND	N	ND
10	97	93	2	ND	ND	N	ND
11	87	95	33	38	N	N	N
12	86	92	29	52	ND	N	ND
13	97	69	2	59	N	N	N
14	92	75	12	0.2	ND	ND	ND
15	92	90	0.4	3	N	N	del (89%)
16	94	83	27	94	N	N	del
17	96	87	3	1	N	N	N
18	92	100	4	38	N	N	del (14%)
19	90	94	10	100	ND	ND	ND
20	92	98	15	ND	ND	N	ND
21	94	97	1	5	N	N	del (94%)
22	98	69	4	75	N	N	del (96%)
23	90	96	10	27	N	N	del (40%)
24	86	100	3	16	N	N	del (79%)
25	87	93	16	6	ND	ND	ND
26	87	97	7	12	ND	ND	ND
27	84	98	ND	2	N	N	N
28	92	96	ND	ND	ND	ND	ND
29	92	87	50	26	N	del (90%)	ND
30	99	90	60	50	N	del/del (98%)	N
31	92	93	3	80	N	del (98%)‖	N
32	91	100	6	68	N	del (92%)‖	N
33	86	100	1	96	N	del (89%)‖	N
34	91	100	90	90	N	del (96%)¶	N
35	60	98	36	71	N	del (60%)‖	del (29%)
36	97	96	87	16	N	del (93%)¶	del (93%)
37	82	100	53	85	N	del (82%)‖	del (60%)
38	95	99	73	ND	N	del (85%)¶	N
39	90	100	91	97	N	del (88%)¶	N
40	97	100	68	0,1	N	del (96%)‖	N
41	92	100	50	26	N	del (87%)‖	N
42	96	100	30	85	N	N	del
43	90	95	12	45	del (90%)	N	del (76%)
44	92	92	5	10	del (86%)	N	del (87%)
45	91	89	58	4	del (85%)	N	N
46	97	99	62	9	del (91%)	N	del (70%)
47	90	95	10	78	del (90%)	N	N
48	92	99	52	65	del (90%)	N	N
49	97	100	2	45	del (87%)	N	N
50	99	98	42	57	del (89%)l	N	del (60%)

CLL no.	CD19*	CD5†	ZAP-70‡	CD38§	11q (ATM)	17p (p53)	13q
1	95	87	19	ND	ND	N	ND
2	94	100	42	17	N	N	N
3	94	100	72	16	N	N	del (95%)
4	92	96	30	ND	ND	ND	ND
5	86	60	100	85	N	N	N
6	96	98	64	74	del (90%)	N	N
7	91	69	29	7	N	N	N
8	94	99	41	26	ND	N	ND
9	99	100	32	14	ND	N	ND
10	97	93	2	ND	ND	N	ND
11	87	95	33	38	N	N	N
12	86	92	29	52	ND	N	ND
13	97	69	2	59	N	N	N
14	92	75	12	0.2	ND	ND	ND
15	92	90	0.4	3	N	N	del (89%)
16	94	83	27	94	N	N	del
17	96	87	3	1	N	N	N
18	92	100	4	38	N	N	del (14%)
19	90	94	10	100	ND	ND	ND
20	92	98	15	ND	ND	N	ND
21	94	97	1	5	N	N	del (94%)
22	98	69	4	75	N	N	del (96%)
23	90	96	10	27	N	N	del (40%)
24	86	100	3	16	N	N	del (79%)
25	87	93	16	6	ND	ND	ND
26	87	97	7	12	ND	ND	ND
27	84	98	ND	2	N	N	N
28	92	96	ND	ND	ND	ND	ND
29	92	87	50	26	N	del (90%)	ND
30	99	90	60	50	N	del/del (98%)	N
31	92	93	3	80	N	del (98%)‖	N
32	91	100	6	68	N	del (92%)‖	N
33	86	100	1	96	N	del (89%)‖	N
34	91	100	90	90	N	del (96%)¶	N
35	60	98	36	71	N	del (60%)‖	del (29%)
36	97	96	87	16	N	del (93%)¶	del (93%)
37	82	100	53	85	N	del (82%)‖	del (60%)
38	95	99	73	ND	N	del (85%)¶	N
39	90	100	91	97	N	del (88%)¶	N
40	97	100	68	0,1	N	del (96%)‖	N
41	92	100	50	26	N	del (87%)‖	N
42	96	100	30	85	N	N	del
43	90	95	12	45	del (90%)	N	del (76%)
44	92	92	5	10	del (86%)	N	del (87%)
45	91	89	58	4	del (85%)	N	N
46	97	99	62	9	del (91%)	N	del (70%)
47	90	95	10	78	del (90%)	N	N
48	92	99	52	65	del (90%)	N	N
49	97	100	2	45	del (87%)	N	N
50	99	98	42	57	del (89%)l	N	del (60%)

N indicates normal; and ND, not determined.

Percentage of cells positive for CD19 surface expression.

†

Percentage of cells positive for CD5 surface expression.

†

Percentage of cells positive for ZAP-70 expression.

Percentage of cells positive for CD38 expression.

‖

p53 Mutational status: CLL no. 31, Trp⁹¹X; CLL no. 32, Arg²⁴⁸Gln; CLL no. 33, His¹⁷⁹delinsGlnfsXI; CLL no. 35, His¹⁷⁹Tyr; CLL no. 37, Pro190fsX56; CLL no. 40, Intron 5-6 GT-GC.

Mutation not found by direct sequencing, p53 protein expression confirmed by Western blot.

View Large

This Feature Is Available To Subscribers Only